Tang Ya-ling, Zhu Gui-quan, Hu Lei, Zheng Min, Zhang Jing-yi, Shi Zong-dao, Liang Xin-hua
State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, China.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Apr;109(4):541-7. doi: 10.1016/j.tripleo.2009.11.007. Epub 2010 Feb 24.
The aim of this study was to investigate the effect of intra-articular sodium hyaluronate (SH) injections on the main components of plasminogen activator (PA) system in the synovial fluid of temporomandibular joint (TMJ) osteoarthritis (OA).
Forty patients diagnosed with TMJ OA and 20 healthy control subjects were included in this study. Synovial fluid was collected in the OA group and the healthy group at baseline. The OA patients were randomly divided into 2 groups (20 patients for each group): One group received 5 injections of SH, and the other received 5 injections of physiologic saline solution in the upper joint space at weekly intervals. Synovial fluid was collected before and after treatment. Urokinase-type PA (uPA), soluble uPA receptor (suPAR) and PA inhibitor 1 (PAI-1) levels in synovial fluid were quantified by enzyme-linked immunosorbent assay.
The OA patients had significantly higher uPA activity and levels of uPA (median 80.01 ng/L), suPAR (median 7.54 ng/L), and PAI-1 (median 54.9 ng/mL) than the healthy control subjects (median 20.47 ng/L uPA, 2.34 ng/L suPAR, and 19.9 ng/mL PAI-1; (P < .05). The uPA activity and levels of uPA, suPAR, and PAI-1 were significantly decreased after SH injections in TMJs of OA patients (P < .05), and there was no difference after saline injection. Visual analog pain score reduction correlated with changes in uPA and uPAR levels as well as uPA activity.
The effects of SH on PA system provide new insight into a possible underlying mechanism by which SH alleviates pain of patients with TMJ OA.
本研究旨在探讨关节腔内注射透明质酸钠(SH)对颞下颌关节(TMJ)骨关节炎(OA)患者滑液中纤溶酶原激活物(PA)系统主要成分的影响。
本研究纳入了40例诊断为TMJ OA的患者和20名健康对照者。在基线时收集OA组和健康组的滑液。OA患者被随机分为2组(每组20例):一组接受5次SH注射,另一组在上关节腔每周注射1次生理盐水,共注射5次。在治疗前后收集滑液。通过酶联免疫吸附测定法定量滑液中尿激酶型PA(uPA)、可溶性uPA受体(suPAR)和PA抑制剂1(PAI-1)的水平。
OA患者的uPA活性以及uPA(中位数80.01 ng/L)、suPAR(中位数7.54 ng/L)和PAI-1(中位数54.9 ng/mL)水平显著高于健康对照者(uPA中位数20.47 ng/L、suPAR中位数2.34 ng/L、PAI-1中位数19.9 ng/mL;P <.05)。OA患者TMJ注射SH后,uPA活性以及uPA、suPAR和PAI-1水平显著降低(P <.05),注射生理盐水后无差异。视觉模拟疼痛评分的降低与uPA和suPAR水平以及uPA活性的变化相关。
SH对PA系统的作用为SH减轻TMJ OA患者疼痛的潜在机制提供了新的见解。